丙型肝炎病毒基因Ⅱ型感染对干扰素治疗的应答反应

Response of Patients with HCV Genotype Ⅱ Infection to IFNα

对 31例丙肝病人进行基因分型及干扰素治疗。其中 2 7例 HCV基因 型感染病人治疗结束时的应答率为92 .6 % (生化 )及 6 3% (病毒 ) ,一年的稳定应答率为 2 6 % (生化及病毒学 ) ,不应答率为 8.4%。结论 :国人 HCV 型感染对干扰素治疗有良好的近期应答 ,如何提高稳定应答率 ,减少复发是临床研究应注意的问题。

To evaluate the response of patients with HCV genetype Ⅱ infection to IFNα,HCV genotypes in 31 cases of chronic hepatitis C were determined by RFLP method.The biochemical and virological responses to standard IFNα therapy were analyzied.The results showed that in 27 cases of HCV genetype Ⅱ infection,the end of treatment response (ETR) to IFNα was 92.6% (biochemistry),63% (virology).The sustained response (SR) was 26% (both biochemistry and virology),nonresponse (NR) was 8.4%.It is indicated that patients with HCV genotype Ⅱ infection have a good ETR to IFNα therapy;that early treatment,prolonged and combined therapy may enhance SR.